Bronchitis News and Research RSS Feed - Bronchitis News and Research

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).
Zebrafish may hold key to unlocking a leading cause of respiratory diseases

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans. [More]
Study identifies link between higher levels of exposure to pollution and lung health in European citizens

Study identifies link between higher levels of exposure to pollution and lung health in European citizens

New data has identified a clear link between higher levels of exposure to air pollution and deteriorating lung health in adult European citizens. [More]
Higher pollution levels linked to deteriorating lung health among adult European citizens

Higher pollution levels linked to deteriorating lung health among adult European citizens

New data has identified a clear link between higher levels of exposure to air pollution and deteriorating lung health in adult European citizens. This study confirms previous findings that children growing up in areas with higher levels of pollution will have lower levels of lung function and a higher risk of developing symptoms such as cough and bronchitis symptoms. [More]
Greater Toronto Area continues to violate Canada-wide standards for ozone air pollution

Greater Toronto Area continues to violate Canada-wide standards for ozone air pollution

A new study shows that while the Greater Toronto Area has significantly reduced some of the toxins that contribute to smog, the city continues to violate the Canada-wide standards for ozone air pollution. [More]

Boehringer Ingelheim announces FDA acceptance of NDA filing for tiotropium and olodaterol FDC

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
Study finds link between common respiratory diseases and increased risk of lung cancer

Study finds link between common respiratory diseases and increased risk of lung cancer

Links between a number of common respiratory diseases and an increased risk of developing lung cancer have been found in a large pooled analysis of seven studies involving more than 25,000 individuals. [More]
COPD overlooked in cardiovascular patients

COPD overlooked in cardiovascular patients

More than a quarter of patients with cardiovascular disease and a history of smoking also have air flow limitation compatible with chronic obstructive pulmonary disease, Japanese study data show. [More]
Research report on global market for respiratory devices

Research report on global market for respiratory devices

The worldwide respiratory device market continues to grow despite economic downturns mainly due to the aging of the world population and increasing incidence of COPD. [More]
Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
LINX Reflux Management System safe for patients suffering from GERD, shows new data

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Torax Medical today announced the release of new data from two leading U.S. medical centers that further establishes the LINX Reflux Management System as a safe and effective procedure for patients suffering from gastroesophageal reflux disease (GERD). [More]
Motivational interviewing reduces secondhand smoke exposure among children living in households

Motivational interviewing reduces secondhand smoke exposure among children living in households

A Johns Hopkins-led research team has found that motivational interviewing, along with standard education and awareness programs, significantly reduced secondhand smoke exposure among children living in those households. [More]
Researchers develop virtual platform that measures level of addiction of smokers

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of 
lung cancer cases and the development of 29 more different conditions. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD). [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. [More]
Study shows commonly used statin drug does not reduce acute COPD exacerbations

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA. [More]
Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that will affect their lung function by the age of 6 years, according to researchers at CHU Sainte-Justine Hospital and the University of Montreal. [More]